Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 15/20 | 0.51 |
| ▸ | CSNK1D | P48730 | 12/20 | 0.51 |
| ▸ | BTK | Q06187 | 3/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.37 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16709036 | 0.89 | CSNK1E (0.52) | CSNK1ECSNK1DBTK | |
| SCHEMBL16711298 | 0.88 | CSNK1E (0.56) | CSNK1ECSNK1D | |
| SCHEMBL16701001 | 0.88 | CSNK1E (0.53) | CSNK1ECSNK1DBTK | |
| SCHEMBL16700433 | 0.88 | CSNK1E (0.53) | CSNK1ECSNK1DBTK | |
| SCHEMBL16700994 | 0.87 | CSNK1E (0.52) | CSNK1ECSNK1DBTKTGFBR1TGFBR2 | |
| SCHEMBL16700443 | 0.87 | CSNK1E (0.53) | CSNK1ECSNK1DBTKTGFBR1TGFBR2 | |
| SCHEMBL16700350 | 0.86 | CSNK1E (0.51) | CSNK1ECSNK1DBTKTGFBR1TGFBR2 | |
| SCHEMBL16699760 | 0.85 | CSNK1E (0.50) | CSNK1ECSNK1DBTKTGFBR1TGFBR2 | |
| SCHEMBL16699529 | 0.83 | CSNK1E (0.48) | CSNK1ECSNK1DBTKTGFBR1TGFBR2 | |
| SCHEMBL16701068 | 0.83 | CSNK1E (0.54) | CSNK1ECSNK1DBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3068785-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-06-26 | — | — | EP | disclosed |
| US-20160122358-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-05 | — | — | US | disclosed |
| US-9273058-B2 | Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122358-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1E, CSNK1A1, CSNK1G1 | CSNK1E 1/4885CSNK1D 7/4885BTK 1624/4885 |
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1E, CSNK1A1, CSNK1G1 | CSNK1E 1/4885CSNK1D 7/4885BTK 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.